We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

The National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG Extend their Collaboration to Investigate the Immuno-Competence of Urothelial Cancer Patients Receiving Immunotherapy

Product News   Oct 23, 2018

 
The National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG Extend their Collaboration to Investigate the Immuno-Competence of Urothelial Cancer Patients Receiving Immunotherapy
FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

Scientists on Standby: Supporting Recruitment of Scientists for COVID-19 Testing

Product News

Scientists on Standby is a portal enabling scientists with relevant skills and experience to volunteer their time, expertise and support for COVID-19 screening and testing.

READ MORE

New Collaboration Aims to Increase COVID-19 Reagent Production

Product News

OXGENE™ and The Native Antigen Company have announced a collaboration to scale up their antigen manufacturing capabilities to deliver high-purity, recombinant proteins for the development of diagnostics and vaccines.

READ MORE

Neoantigen Specific Peptide Synthesis Service for Precision Immuno-oncology Therapeutic Development

Product News

The new service from GenScript aims to overcome the challenges of manufacturing difficult neoantigen peptides critical to personalized cancer vaccine and T-cell therapy generation.

READ MORE

Like what you just read? You can find similar content on the communities below.

Cancer Research Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE